Advertisement
IDXX vs SNN
Which Stock Would AI Choose? IDEXX Laboratories (IDXX) vs. Smith & Nephew (SNN) Stock Comparison
Key Takeaways
- IDEXX Laboratories (IDXX) operates in veterinary diagnostics and software, delivering 14% reported revenue growth in Q1 2026 with raised full-year guidance.
- Smith & Nephew (SNN) focuses on medical devices including orthopedics and sports medicine, reporting Q1 sales beat alongside a $500 million share buyback program.
- Both stocks face upcoming Q2 2026 earnings releases on or around August 4, serving as near-term catalysts amid broader healthcare sector positioning.
- IDEXX Laboratories (IDXX) has shown a steeper year-to-date decline compared to Smith & Nephew (SNN), which has traded with relatively more stability in recent weeks.
- Analyst consensus leans Buy for IDEXX Laboratories (IDXX) with higher price targets, while Smith & Nephew (SNN) carries mostly Hold ratings.
- Relative performance highlights trade-offs between growth-oriented veterinary exposure and established medical device operations with returning capital initiatives.
Introduction
Investors and traders often compare stocks within the healthcare sector to evaluate relative performance, sector exposure, and growth potential in varying market conditions. IDEXX Laboratories (IDXX) and Smith & Nephew (SNN) represent distinct niches—veterinary diagnostics versus orthopedic and sports medicine devices—making them relevant for those assessing medical technology equities. This comparison provides factual context on business models, recent market activity, and observable factors that may influence positioning, aiding portfolio construction without implying specific recommendations.
IDXX Overview and Recent Performance
IDEXX Laboratories (IDXX) develops and commercializes diagnostic products and software primarily for companion animal healthcare. In recent weeks, the stock has reflected broader market pressures, posting a year-to-date decline of approximately 15% as of late July 2026, underperforming the S&P 500. Q1 2026 results showed 14% reported revenue growth and 11% organic growth, with raised full-year revenue and earnings per share (EPS) guidance. Upcoming Q2 results scheduled for August 4, followed by an Investor Day on August 13, have kept attention on recurring diagnostics revenue trends and operational execution.
SNN Overview and Recent Performance
Smith & Nephew (SNN) manufactures medical devices focused on orthopedics, sports medicine, and advanced wound management. Recent market activity has featured relative price stability with a modest year-to-date decline near 2-4% as of early August 2026. The company delivered a Q1 sales beat and initiated a $500 million share buyback, signaling confidence in cash flow. Positive product developments, including FDA De Novo classification for the TESSA spatial surgery system in recent months, have contributed to sentiment alongside upcoming Q2 and first-half 2026 results expected around August 4.
Trending AI Robots
Tickeron’s Trending AI Robots page curates top-performing AI trading bots from hundreds available across thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, allowing users to review statistics and historical results directly. The platform provides transparent data on bot characteristics to support informed evaluation of automated trading approaches.
Head-to-Head Comparison
IDEXX Laboratories (IDXX) and Smith & Nephew (SNN) operate in adjacent yet differentiated healthcare segments, with IDEXX Laboratories (IDXX) emphasizing recurring veterinary diagnostics revenue and Smith & Nephew (SNN) relying on device sales and procedural volumes in orthopedics. Recent momentum shows IDEXX Laboratories (IDXX) benefiting from raised guidance after strong Q1 results, while Smith & Nephew (SNN) highlights capital return via buyback and new product clearances. Risk factors differ: IDEXX Laboratories (IDXX) faces potential volatility tied to pet healthcare spending cycles, whereas Smith & Nephew (SNN) contends with reimbursement and procedural recovery dynamics. Sector exposure remains healthcare-oriented, with market sentiment reflecting analyst preference for growth at IDEXX Laboratories (IDXX) versus steadier positioning at Smith & Nephew (SNN).
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings catalysts, and relative positioning in recent market activity, Tickeron’s AI would currently assign a modest probabilistic edge to Smith & Nephew (SNN) for nearer-term stability, though IDEXX Laboratories (IDXX) demonstrates stronger growth signals from raised guidance. Outcomes remain dependent on upcoming earnings and broader market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a Hold and SNN is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green whileSNN’s FA Score has 1 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- SNN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 5 TA indicator(s) are bullish while SNN’s TA Score has 6 bullish TA indicator(s).
- IDXX’s TA Score: 5 bullish, 4 bearish.
- SNN’s TA Score: 6 bullish, 3 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а +2.71% price change this week, while SNN (@Medical/Nursing Services) price change was +3.24% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.50%. For the same industry, the average monthly price growth was -7.49%, and the average quarterly price growth was -17.67%.
Reported Earning Dates
IDXX is expected to report earnings on Aug 04, 2026.
SNN is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+2.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| IDXX | SNN | IDXX / SNN | |
| Capitalization | 44.1B | 13.1B | 337% |
| EBITDA | 1.56B | 1.53B | 102% |
| Gain YTD | -17.362 | -2.351 | 738% |
| P/E Ratio | 41.14 | 22.04 | 187% |
| Revenue | 4.45B | 6.16B | 72% |
| Total Cash | 201M | 419M | 48% |
| Total Debt | 1.11B | 3.45B | 32% |
IDXX | SNN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 30 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 4 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 16 | 77 | |
PRICE GROWTH RATING 1..100 | 57 | 49 | |
P/E GROWTH RATING 1..100 | 69 | 84 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNN's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for IDXX (78). This means that SNN’s stock grew significantly faster than IDXX’s over the last 12 months.
SNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as IDXX (100). This means that SNN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SNN (77). This means that IDXX’s stock grew somewhat faster than SNN’s over the last 12 months.
SNN's Price Growth Rating (49) in the Medical Specialties industry is in the same range as IDXX (57). This means that SNN’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's P/E Growth Rating (69) in the Medical Specialties industry is in the same range as SNN (84). This means that IDXX’s stock grew similarly to SNN’s over the last 12 months.
| IDXX | SNN | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 69% | 4 days ago 60% |
| Momentum ODDS (%) | 4 days ago 67% | 4 days ago 54% |
| MACD ODDS (%) | 4 days ago 66% | 4 days ago 67% |
| TrendWeek ODDS (%) | 4 days ago 59% | 4 days ago 55% |
| TrendMonth ODDS (%) | 4 days ago 53% | 4 days ago 57% |
| Advances ODDS (%) | 6 days ago 58% | 6 days ago 57% |
| Declines ODDS (%) | 12 days ago 70% | 4 days ago 56% |
| BollingerBands ODDS (%) | 4 days ago 62% | 4 days ago 51% |
| Aroon ODDS (%) | 4 days ago 70% | 4 days ago 54% |
Advertisement
IDXX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with ALGN. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then ALGN could also see price increases.
| Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
|---|---|---|---|---|
| IDXX | 100% | +0.05% | ||
| ALGN - IDXX | 50% Loosely correlated | -2.45% | ||
| SYK - IDXX | 48% Loosely correlated | -6.42% | ||
| BLCO - IDXX | 45% Loosely correlated | -0.47% | ||
| SNN - IDXX | 44% Loosely correlated | -2.38% | ||
| STE - IDXX | 40% Loosely correlated | -1.22% | ||
More | ||||
SNN and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNN has been loosely correlated with ENOV. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNN jumps, then ENOV could also see price increases.
| Ticker / NAME | Correlation To SNN | 1D Price Change % | ||
|---|---|---|---|---|
| SNN | 100% | -2.38% | ||
| ENOV - SNN | 47% Loosely correlated | -0.51% | ||
| OFIX - SNN | 47% Loosely correlated | +0.08% | ||
| MDT - SNN | 45% Loosely correlated | -0.37% | ||
| GEHC - SNN | 44% Loosely correlated | -2.75% | ||
| SYK - SNN | 44% Loosely correlated | -6.42% | ||
More | ||||